Background--Early discontinuation of P2Y 12 antagonists post-percutaneous coronary intervention may increase risk of stent thrombosis or nonstent recurrent myocardial infarction. Our aims were to (1) analyze the early discontinuation rate of P2Y 12 antagonists post-percutaneous coronary intervention, (2) explore factors associated with early discontinuation, and (3) analyze the risk of major adverse cardiovascular events (death, acute coronary syndrome, revascularization, or stroke) associated with discontinuation from a prespecified prescribing instruction of 1 year.
P oor medication adherence is often associated with adverse patient events across multiple disease outcomes. This is of particular concern in the setting of modern cardiac intervention with stent implantation for acute coronary syndromes (ACS), where discontinuation of antiplatelet therapy risks both stent stenosis and non-stentrelated myocardial infarction (MI). As such, the use of dual antiplatelet therapy (DAPT), aspirin plus a P2Y 12 inhibitor, in patients undergoing coronary revascularization is an established treatment strategy in the prevention of short-and longterm thrombotic complications. [1] [2] [3] Current guidelines recommend a minimum of 12 months of DAPT for patients presenting with ACS undergoing coronary percutaneous coronary intervention (PCI) with stent implantation, reduced to at least 6 months in the presence of risk factors for bleeding. 4, 5 In patients with stable coronary artery disease, a minimum of 6 months is recommended following drug eluting stents implantation and at least 1 month following a bare metal stent or in those with a high risk of bleeding. The presence of comorbidities, such as atrial fibrillation (AF), may necessitate the need for concomitant anticoagulation and therefore shorter durations of DAPT may be warranted. Likewise, the need to undergo surgery in the future may also mandate shorter durations of DAPT.
A number of observational studies have shown that an increase in major adverse cardiac events is associated with a delay in access to prescriptions for P2Y 12 inhibitors following coronary PCI 6, 7 or premature discontinuation following an MI or stent implantation. [8] [9] [10] [11] [12] [13] Rates of discontinuation vary between studies, with some reporting 13% discontinuation within 30 days 10 and others up to 40% to 50% within 1 year. 8, 9 However, these studies have not identified the intended duration of therapy postdischarge or taken account of comorbidities that may warrant shorter durations of DAPT. Furthermore, the study populations were predominantly medically treated ACS 8, 14 or, in the case of the PARIS (Patterns of Non-Adherence to Antiplatelet Regimens in Stented Patients) registry, predominantly stable angina patients undergoing PCI. 15 Our objectives were to (1) analyze the rate of early discontinuation of clopidogrel following discharge from hospital in a post-PCI population where the duration of DAPT was specified for 1 year, (2) explore potential factors associated with discontinuation in prescribing, and (3) analyze the risk of death and major cardiovascular events associated with discontinuation.
Methods
We undertook a retrospective observational cohort study using linked anonymized healthcare data from the SAIL (Secure Anonymised Information Linkage) Databank 16, 17 for patients undergoing PCI at a tertiary cardiac center in Wales. The study population was identified from the cardiac intervention database and included patients who were discharged from the hospital (between January 2011 and November 2015) following PCI for either stable or acute coronary artery disease. Follow-up was for 18 months. Patients who underwent coronary artery bypass grafting (CABG) during the index admission or had a previous or contemporary diagnosis of AF were excluded from the study.
This study makes use of anonymized patient data; therefore, informed consent was not required. Approval for the study was granted by the SAIL IGRP (Information Governance Review Panel). All data can be made available to researchers by standard SAIL IGRP protocols.
Approval for data access and processing was granted by the SAIL independent Information Governance Review Panel (IGRP) project number: 0441. Permission was granted from the respective health board data custodians of the Cardiac intervention dataset and the hospital discharge prescribing data sets.
Data Sets and Linkage
The cardiac intervention data set contains procedural, clinical, and demographic data on patients undergoing PCI. Information on the prescribing of antithrombotic therapy was obtained from the hospital discharge summaries. These data sets were linked to the WLGP (Welsh Longitudinal General Practice) data set to record the continuity of antithrombotic therapy and presence of comorbidities, risk factors, and demographics. 18 Date of death, where relevant, was identified form the ADDE (Annual District Death Extract) 19 containing mortality records from the ONS (Office of National Statistics), and deprivation quintile was assigned using the WIMD (Welsh Index of Multiple Deprivation), an area-based deprivation measure. 20 For each patient hospitalized in Wales, the PEDW (Patient Episode Database for Wales) records the admission and discharge dates, diagnoses, and operational procedures and demographic data. Date of death is also recorded when the patient dies within the hospital. These records are completed at finished consultant episode. Within each finished consultant episode, 1 primary and ≥1 secondary diagnosis, using the International Classification of Disease, Tenth Revision (ICD-10), are recorded. Operational and procedural codes are also applied for each finished consultant episode following the OPCS-4 (Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4). The PEDW was used to describe cardiac revascularization (either PCI or CABG) and major bleeding events preceding the index
Clinical Perspective
What Is New?
• In this real-world study following patients discharged postpercutaneous coronary intervention where the duration of dual antiplatelet therapy was known, discontinuation of P2Y 12 antagonist therapy was low and much lower than reported in other studies. • Despite the low discontinuation rate, it was an important predictor of major adverse outcomes in this population, especially in those with concomitant bleeding.
What Are the Clinical Implications?
• Discontinuation of P2Y 12 antagonist therapy earlier than intended is associated with an increased rate of adverse events, highlighting the importance of processes optimizing concordance with evidence-based preventative therapy post-percutaneous coronary intervention.
admission (see Table S1 for ICD-10 codes used to identify bleeding events). Major bleeding events included gastrointestinal bleeds, intracranial bleeds, urinary tract bleeds, and airway bleeds. Both the PEDW and WLGP data sets were searched for past history or contemporary diagnosis of vascular disease (peripheral artery disease or aortic plaque), AF/flutter, MI, Ischemic stroke, thromboembolism, and heart failure.
Index Event Data
For each patient, the first entry in the cardiac intervention database occurring during the study period was identified as the index intervention. Dates of admission and discharge were identified either side of the index intervention using the PEDW data set. Prescribing data corresponding to the index intervention were extracted from the electronic discharge summaries. Where an electronic discharge summary was not available, paper copies of the discharge summary, where available, were searched and the prescribing data were recorded.
P2Y 12 Antagonist Prescribing and Discontinuation
Prescribing of P2Y 12 antagonists postdischarge was recorded within consecutive 3-month periods following the date of discharge from hospital. Discontinuation was deemed to have occurred when there was a 3-month period without a P2Y 12 antagonist prescription before the intended date of treatment cessation. The precise time to discontinuation is unknown, but was approximated as the center point within the first 3month period where no P2Y 12 antagonist had been prescribed, that is, 46 days for the first 3-month period; 137 days for the second 3-month period; and 228, 319, 411, and 501 days for the third to sixth three-month periods, respectively.
Statistical Analyses
Baseline variables and patient characteristics, including demographics, lifestyle behaviors, and medical history, are presented as percentages and means with SDs. Differences between those prescribed P2Y 12 therapy for 1 year and all other regimes were compared using the v 2 test for categorical variables and the 2-sample t test for continuous variables. A Cox proportional hazards model was used to determine the baseline characteristics associated with "time to discontinuation" from the prescribing instruction at the point of discharge from the hospital. Bleeding subsequent to PCI, occurring during the period of intended prescription duration, was included as a time-dependent covariate. Hazard ratios (HRs) and 95% CIs were calculated for the respective clinical variables. In analyzing time to discontinuation, death during the follow-up was treated as a censoring event, and hence we assumed that the time to death (or other loss to follow-up) was not related to the time-to-attrition distribution.
The primary clinical end point was a combination of death of any cause, subsequent readmission to hospital for an MI, unstable angina, acute ischemic heart disease, ischemic stroke or transient ischemic attack, or readmission after 30 days from the index discharge date for either CABG or recurrent coronary PCI (see Tables S2 and S3 for ICD-10 and OPCS codes used to establish these end points). A Cox proportional hazards model was used to determine characteristics of the cohort associated with this adverse composite outcome; specifically the effect of discontinuation was modeled as a time-dependent covariate. In estimating the effect of discontinuation, we attempted to control for expected risk factors by including the key baseline characteristics in the Cox model. In addition, we had to control for effects of bleeding, again as a time-dependent covariate. We created a covariate with 4 levels representing the overall timedependent classification: no discontinuation and no bleed, discontinuation occurred but no bleed, bleed occurred but no discontinuation, and, finally, both events have occurred. For those patients with an adverse outcome, only discontinuation and/or bleeding events occurring before the end point were included in the analysis. All models were run in SPSS software (version 22.0; SPSS, Inc., Chicago, IL). Variables were initially considered separately in univariable analyses; the final multivariable Cox model was selected by minimizing the Akaike information criterion (with a comparison to model selection using Bayesian information criteria).
Results

Study Population
Of the 5532 patients undergoing PCI during the study period, 3066 (55.4%) were discharged and had a complete linked healthcare data set available ( Figure 1 ). A further 397 (7.2%) were excluded who had AF or underwent a CABG procedure during the index admission. Of the final 2770 patients meeting the inclusion criteria, 2090 (75.5%) were prescribed clopidogrel for 1 year (plus aspirin 75 mg once-daily for life). Of this cohort, mean age was 63.2 years, 73.5% were male, and 86.5% underwent PCI for an ACS (Table 1 ). In comparison with those prescribed any other regimen on discharges, these patients had a lower mean age; lower rate of previous diagnoses for ischemic heart disease; MI, previous coronary revascularization, heart failure, or dyslipidemia; and were less likely to have been prescribed in the year preceding the index event either aspirin, P2Y 12 inhibitors, or statins (further comparisons between those included and those excluded [with or without discharge prescribing data available] are contained in Table S4 ).
Clopidogrel Discontinuation
Rate of discontinuation during the periods 0 to 3, 3 to 6, 6 to 9, and 9 to 12 months postdischarge was 1.1%, 2.6%, 3.7%, and 6.1%, respectively ( Figure 2 ). Between 12 and 15 months, 47% had discontinued clopidogrel and 76.2% by 15 to 18 months.
Factors associated with clopidogrel discontinuation during the first 12 months included: increasing age, hypertension, ischemic heart disease, previous MI, previous coronary revascularization, ischemic stroke, heart failure, vascular disease, previous bleeding events, and bleeding during the follow-up period ( Figure 3 ). After adjusting for all baseline characteristics, previous revascularization, previous ischemic stroke, and age groups ≥80 years were independently associated with discontinuation ( Table 2 ).
Death and Major Cardiovascular Events
Incidence of death or major cardiovascular events in those who had no discontinuation or bleeding events postdischarge was 9.5 per 100 person-years (95% CI, 8.39-10.74); in patients who had discontinued clopidogrel but had no bleeding events, the incidence was 15.2 (95% CI, 6.72-24.24); in patients who had a bleeding event but no discontinuation, it was 41.9 (95% CI, 21.38-60.10); and in patients who had both bleeding and discontinuation, it was 64.6 per 100 person-years (95% CI, 1.29-127.96).
Patient characteristics associated with death or major cardiovascular events included: age ≤49 or ≥60 compared with those aged 50 to 59, hypertension, previous MI, previous coronary revascularization, ischemic stroke, heart failure, vascular disease, thromboembolism, diabetes mellitus, chronic kidney disease, chronic liver disease, clopidogrel discontinuation, and bleeding during follow-up ( Figure 4 ).
Characteristics independently associated with death or major cardiovascular events in a multivariable Cox Journal of the American Heart Association proportional hazards model included age <49 and ≥70 years compared with those aged 50 to 59; previous coronary revascularization; and a history of thromboembolism, chronic kidney disease stage 4 or 5, and ischemic stroke ( Table 3) . After adjustment for these factors, the time-dependent effects of discontinuation and bleeding were significantly associated with death or major cardiovascular events. For discontinuation alone, there was an estimated HR of 1.82 (95% CI, 1.01-3.30) compared with patients with no discontinuation and no bleeding events. Similarly, the occurrence of bleeding alone in those without discontinuation was associated with an increased risk of death or major cardiovascular events (HR=5.30; 95% CI, 3.14-8.94). Notably, the combined effect of having both discontinuation and bleeding was associated with the greatest likelihood of adverse events (HR=9.34; 95% CI, 3.39-25.70).
Model selection was also explored using Bayesian information criteria. This resulted in selection of fewer patient characteristics; however, the effects of bleeding and clopidogrel discontinuation were retained in the final model as statistically significant.
For completeness, the characteristics associated with the individual outcomes of MI, stroke, revascularization, and death are presented in Tables S5 and S6 . Assessment of risk factors associated with bleeding was not a primary objective of this study, but nonetheless an important consideration. In a multivariable analysis, previous bleeding events (HR=2.82; 95% CI, 1.67-4.76), chronic kidney disease (HR=6.15; 95% CI, 2.22-17.08), and chronic liver disease (HR=3.62; 95% CI, 1.14-11.51) were independently associated with bleeding events during follow-up (Table S7 ). These variables were not independently associated with risk of clopidogrel discontinuation.
Discussion
This is the first real-world outcome study examining the rate of clopidogrel discontinuation following PCI where the intended prescribing duration of DAPT is known. Notably, discontinuation of P2Y 12 inhibitor therapy is low in this population, where a specified prescribing instruction to continue for 12 months is provided, in contrast to other studies where the prescribing duration was not known. Furthermore, despite the low discontinuation rate, discontinuation was still identified as an important predictor of adverse outcomes in this population, especially in those with concomitant bleeding.
The observed rate of discontinuation is in marked contrast with findings from previous studies, where it had been suggested that up to a half of patients post-MI discontinue therapy within 12 months. 8 We note that this was observed in a historical ACS patient group who were predominantly treated medically as opposed to receiving contemporary PCI therapy. Nevertheless, our observed rate of discontinuation was still lower than expected. There are a number of possible inhibitors post-PCI, improved communication of the prescribing intention from secondary to primary care, and, possibly, the availability of free prescriptions to all patients in Wales. However, addressing these questions was outside the scope of this study. Among those patients who discontinued clopidogrel earlier than the initial intended period, the hazard of death or major cardiovascular events was greater compared with those who continued therapy, as expected and in keeping with previous studies. 8, 21 Other independent predictors of adverse outcomes included ischemic stroke and previous revascularization; both likely markers of diffuse or severe cardiovascular disease. However, both ischemic stroke and previous revascularization were also predictors of discontinuation. Whether these contrasting findings are a consequence of shared risk factors, such as aging, comorbidities, or the index PCI, being a consequence of poor adherence to medication is unknown.
Other independent predictors of discontinuation included advanced age, which has previously been shown to be a predictor of early discontinuation of clopidogrel post-MI. Bleeding events measured as a time-dependent variable were not an independent predictor of discontinuation, contrasting with observations from a previous study. 8 It is possible that those patients with previous bleeding events or at higher risk of bleeding may have been instructed for a shorter course of DAPT at discharge and were therefore not included in this analysis. The exclusion of patients undergoing CABG and those with AF, both groups of which are at higher risk of bleeding and subsequent discontinuation of P2Y 12 treatment, may explain this observation. We found no association between deprivation quintiles and clopidogrel discontinuation, nor deprivation quintiles and major adverse outcomes in univariable analyses. Therefore, deprivation index was not included in the final multivariable analyses.
In this study, we documented gastrointestinal bleeds, intracranial bleeds, urinary tract bleeds, and airway bleeds in order to be consistent with previous studies, 22 but bleeding events occurring in other organ systems may have had major clinical outcomes and resulted in cessation of therapy. However, the lack of an accepted standard for defining relevant bleeding events and defining their severity in realworld data sets is a recognized limitation for studies such as these.
Bleeding events were also highly predictive of adverse outcomes, as expected. Bleeding is a recognized adverse consequence of antiplatelet therapy and is associated with a greater incidence of death and ischemic events. 1, 3, 23, 24 We found that the greatest risk of death or major cardiovascular events occurred in those with both discontinuation and bleeding events in our cohort. While it is not possible to identify the specific cause of adverse outcomes in this group, it is recognized that contributing factors to worse outcomes include the triggering of prothrombotic and -inflammatory responses following a bleed, combined with discontinuation of antiplatelet therapy leading to a rebound increased risk of ischemic events. While discontinuation was reassuringly low in the first 12 months, it is notable that continuation of prescribing beyond 12 months was high with almost one-quarter (24% [n=427]) of patients still receiving a prescription for clopidogrel between 15 and 18 months after discharge from the index event. Possible reasons for continuation of clopidogrel include recurrent ischemic events; however, we noted that only 22.5% (n=96) within this group had a documented readmission for recurrent major cardiovascular events during follow-up. It is possible that further clinical events occurred that led to a decision to continue or change therapy, although it is unlikely that this was the case for the majority of patients. Given that prescriptions are provided free in Wales, there is no financial disincentive to stop treatment, which may explain the relatively high numbers of patients continuing treatment beyond the recommended period. Given that the data set only examined outcomes up to 18 months, there was insufficient power to explore the relationship between extended prescriptions beyond 12 months and the effect on either cardiovascular events or bleeding attributable to relatively low numbers and short exposure times.
Strengths and Limitations of this Study
We believe that this study further refines our understanding of the impact of P2Y 12 discontinuation on clinical outcomes. By identifying the discharge prescribing intention, we have avoided overestimation by excluding those with shorter durations of DAPT. Thus, although our analysis only evaluates 40% of the entire PCI population, we believe that these patients are representative of the majority of the post-PCI population who are recommended to receive 1 year of DAPT, given that our analysis has excluded patients requiring anticoagulation, those undergoing surgery, and those without a complete linked data set. There were also many clinical and demographic differences between those directed to 1 year of clopidogrel and the remaining group who had greater prevalence of risk factors for both cardiovascular and bleeding events. By keeping those higher-risk patients in the analyses, over-representation of these important risk factors would likely have led to further overestimation of the actual relationship between discontinuation and adverse cardiovascular events. Furthermore, the exclusion of those with AF and/or undergoing CABG, who are at higher risk of bleeding and subsequent discontinuation of P2Y 12 inhibitors, has likely further reduced the rate of discontinuation and the effect of bleeding events leading to discontinuation.
There are several limitations to this study. While we have identified the prescribing intention from the hospital, we were not able to identify the quantity of medication issued from either hospital or primary care; therefore, we were unable to calculate precisely when an individual's prescription would have finished if taken according to instruction. In the WLGP data set, we noted that prescriptions were usually issued every month, but occasionally repeated every 2 months. Within a 3-month period, if no prescription had been issued, it was possible to assume that either a 1-or 2month supply made in the previous quarter had been exhausted. Discontinuation was deemed to have occurred when there was a 3-month period without a P2Y 12 antagonist prescribed. Using this method, we were able to detect periods where we had greater certainty that an individual's prescription was likely to have finished, but we lacked the precision for identification of shorter periods of discontinuation.
As with any observational studies, we cannot determine whether the association between clopidogrel discontinuation and adverse outcomes was causal or may have been confounded by the influence of unrecorded comorbidities, including unrecorded bleeding events, the underutilization of other prognostically relevant medicines, or new undocumented behaviors. The prescribing and potential discontinuation from aspirin was not accounted for in this study. In the UK, aspirin is widely available without a prescription and is inexpensive; therefore, the assessment of aspirin discontinuation from the WLGP data set may have led to classifications of periods of discontinuation when a patient may have self-medicated.
It was not possible to identify the cause of discontinuation in this study. While the recording of prescriptions issued from the WLGP data set is robust, currently it is not possible to identify the dispensing of those prescriptions. Access to prescription dispensing records in addition to the prescribing records from the WLGP data set would have improved the sensitivity of capturing periods "off treatment" and the association between nonadherence as well as discontinuation and adverse outcomes. Furthermore, it is not possible to identify whether patients took the medication as intended, as is the case in most clinical studies. Therefore, this study does not confirm whether compliance with medication and periods of discontinuation could be attributed to either intentional or unintentional patient noncompliance or intentional prescriber discontinuation. It is possible that patients recorded as having discontinued clopidogrel received prescriptions either privately or from outpatient hospital appointments, although rare in Wales, neither of which would have been captured in this study. However, this would likely further increase the true difference in the effect of discontinuation on adverse outcomes.
During the study period, international guidelines changed to preferentially recommending the use of the more-potent P2Y 12 antagonists such as ticagrelor or prasugrel. However, attributable largely to financial restrictions within the Welsh health service, clopidogrel remained the mainstay of treatment for ACS during this time. Although this article addresses the use of clopidogrel post-PCI, we believe this article remains of critical value given that it illustrates the importance of knowing the schedule duration of any therapy before drawing conclusions on the impact of early discontinuation. Although not addressed in this study, one may expect the adverse impact of poor concordance with newer, more-effective therapies to be even greater. Last, this observational study was conducted within a health service that is both accessible and free at the point of care, including the free provision of medication. This should be born in mind when comparing the results of this study with those systems where access to health care and affordability may influence therapy and outcomes at a population level. 
Conclusion
In conclusion, this study has demonstrated that identifying the intended duration of P2Y 12 antagonist therapy on discharge following a PCI is essential for determination of the correct rate of premature discontinuation in real-world outcome studies . The rate of discontinuation was reassuringly low in this patient group and much lower than anticipated in previous studies. While this is reassuring from the population level, at an individual level, discontinuation of P2Y 12 antagonist therapy earlier than the intended duration is associated with an increased rate of adverse events. Our data emphasize the importance of improving processes to ensure optimal concordance with evidence-based preventative therapy post-PCI. In these models we found no significant association between discontinuation and/or bleeding on coronary revascularization. We also calculated the event rate per 100 patient years (table S6 ). In the case of MI, revascularization and stroke there were no patients who had both clopidogrel discontinuation and bleeding events prior to the adverse outcome. *The following variables were included in the model: age; gender; presenting clinical syndrome; hypertension; prior coronary revascularization; prior bleeding events; ischemic stroke; heart failure; vascular disease; thromboembolism; diabetes; CKD stage 4+; chronic liver disease, dyslipidemia; dementia and time dependent variables or clopidogrel discontinuation, bleeding and both discontinuation and bleeding. Only variables associated with one or more outcomes are presented. The final variables were selected in a multivariable co model by minimizing the Akaike information criterion. 
